Inhibitor of lymphocyte activation

• US 20020034507A1
• Filed: 01/17/2001
• Published: 03/21/2002
• Est. Priority Date: 02/28/1997
• Status: Abandoned Application

• Current Assignee: Yasuo Koishihara
• Original Assignee: Yasuo Koishihara
• Inventors: Koishihara, Yasuo
• Application Number:
  US09/760,723
• Publication Number:
  US 20020034507A1
• Time in Patent Office: Days
• US Class Current: 424/130.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

A novel inhibitor of lymphocyte activation is provided.

Said inhibitor of lymphocyte activation comprises, as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO: 1.

Said antibody is preferably anti-HM1.24 antibody, and the inhibitor of lymphocyte activation of the present invention is used as a preventive and/or therapeutic agent of an autoimmune disease, a rejection in organ transplantation, or allergy.

Claims

1. An inhibitor of lymphocyte activation comprising, as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO:

1.

2. An inhibitor according to claim 1 in which the lymphocytes are T cells.

3. An inhibitor according to claim 1 in which the lymphocytes are B cells.

4. An inhibitor according to any of claims 1 to 3 in which the antibody is a monoclonal antibody.

5. An inhibitor according to claim 4 in which the antibody has the constant region of human antibody.

6. An inhibitor according to claim 4 or 5 in which the antibody is a chimeric antibody or a humanized antibody.

7. An inhibitor according to claim 4 in which the antibody is anti-HM1.24 antibody.

8. An inhibitor according to claim 6 in which the antibody is chimeric anti-HM1.24 antibody.

9. An inhibitor according to claim 6 in which the antibody is humanized anti-HM1.24 antibody.

10. An inhibitor according to claim 1 in which the antibody specifically binds to an epitope recognized by anti-HM1.24 antibody.

11. A preventive and/or therapeutic agent for diseases associated with lymphocyte activation, comprising, as an active ingredient, an antibody that specifically binds to a protein having the amino acid sequence as set forth in SEQ ID NO:

1.

12. The preventive and/or therapeutic agent according to claim 11, in which the disease associated with lymphocyte activation is an autoimmune disease, a rejection in organ transplantation, or allergy.